Synonym
Crobenetine Free Base; BIII890; BIII-890; BIII 890
IUPAC/Chemical Name
(2R,6S)-3-((S)-2-(benzyloxy)propyl)-6,11,11-trimethyl-1,2,3,4,5,6-hexahydro-2,6-methanobenzo[d]azocin-10-ol
InChi Key
VCCBCXVFGHTDQN-UODBTFMRSA-N
InChi Code
InChI=1S/C25H33NO2/c1-18(28-17-19-9-6-5-7-10-19)16-26-14-13-25(4)21-11-8-12-22(27)20(21)15-23(26)24(25,2)3/h5-12,18,23,27H,13-17H2,1-4H3/t18-,23+,25-/m0/s1
SMILES Code
C[C@H](OCc1ccccc1)CN2CC[C@]3(c4c(C[C@@H]2C3(C)C)c(O)ccc4)C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
|
Solvent |
mg/mL |
mM |
| Solubility |
| Soluble in DMSO |
0.0 |
100.00 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
379.54
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Laird JM, Carter AJ, Grauert M, Cervero F. Analgesic activity of a novel use- dependent sodium channel blocker, crobenetine, in mono-arthritic rats. Br J Pharmacol. 2001 Dec;134(8):1742-8. doi: 10.1038/sj.bjp.0704428. PMID: 11739251; PMCID: PMC1572907.
2: Meythaler J. BIII-890-CL. Boehringer Ingelheim. Curr Opin Investig Drugs. 2002 Dec;3(12):1733-5. PMID: 12528308.
3: Grauert M, Bechtel WD, Weiser T, Stransky W, Nar H, Carter AJ. Synthesis and structure-activity relationships of 6,7-benzomorphan derivatives as use- dependent sodium channel blockers for the treatment of stroke. J Med Chem. 2002 Aug 15;45(17):3755-64. doi: 10.1021/jm020875j. PMID: 12166948.
4: Dekker LV, Daniels Z, Hick C, Elsegood K, Bowden S, Szestak T, Burley JR, Southan A, Cronk D, James IF. Analysis of human Nav1.8 expressed in SH-SY5Y neuroblastoma cells. Eur J Pharmacol. 2005 Dec 28;528(1-3):52-8. doi: 10.1016/j.ejphar.2005.10.035. Epub 2005 Dec 2. PMID: 16325806.
5: Carter AJ, Grauert M, Pschorn U, Bechtel WD, Bartmann-Lindholm C, Qu Y, Scheuer T, Catterall WA, Weiser T. Potent blockade of sodium channels and protection of brain tissue from ischemia by BIII 890 CL. Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4944-9. doi: 10.1073/pnas.040577097. PMID: 10781102; PMCID: PMC18337.
